Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269728 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HPGDMEN1KMT2ABRD4 | |
| SCHEMBL3269739 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HPGDMEN1KMT2ABRD4 | |
| SCHEMBL3267455 | 0.89 | ABCB1 (0.59) | SMN1; SMN2HPGDKMT2AABCB1KDM4E | |
| SCHEMBL3267459 | 0.89 | ABCB1 (0.59) | SMN1; SMN2HPGDKMT2AABCB1KDM4E | |
| SCHEMBL3266056 | 0.88 | ABCB1 (0.60) | SMN1; SMN2HPGDMEN1KMT2AABCB1 | |
| SCHEMBL3266053 | 0.88 | ABCB1 (0.60) | SMN1; SMN2HPGDMEN1KMT2AABCB1 | |
| SCHEMBL3266062 | 0.88 | ABCB1 (0.60) | SMN1; SMN2HPGDMEN1KMT2AABCB1 | |
| SCHEMBL3920339 | 0.83 | ABCB1 (0.56) | SMN1; SMN2HPGDMEN1KMT2AABCB1 | |
| SCHEMBL3920334 | 0.83 | ABCB1 (0.56) | SMN1; SMN2HPGDMEN1KMT2AABCB1 | |
| SCHEMBL13938082 | 0.81 | ABCB1 (0.53) | ABCB1KDM4EMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326833-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7135483-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| EP-1326833-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | THE PROCTER GAMBLE CO. | 2002-07-25 | — | — | US | disclosed |
| WO-2002032869-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6376514-B1 | PIPERIDINE-DERIVED COMPOUNDS CONTAINING A QUINOLYL GROUP THAT INHIBITS P-GLYCOPROTEIN TRANSPORT PROTEIN ACTIVITY; FOR TREATING CANCER AND OTHER DISEASES | THE PROCTER & GAMBLE CO. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCB11 | SMN1; SMN2 2454/4885HPGD 169/4885MEN1 2708/4885 |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | SMN1; SMN2 2929/4885HPGD 99/4885MEN1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.